Table 1.

Sensitivity analysis assessing the causal relationship between metabolites and gout

Metabolites	N	IVW		MR-egger		Heterogeneity		Pleiotropy
		OR (95%)	p	OR (95%)	p	Q	p	Intercept	p
5alpha-androstan-3beta,17alpha-diol disulfate levels	5	0.554 (0.381, 0.805)	0.002	0.189 (0.038, 0.944)	0.135	3.102	0.541	0.099	0.271
Pantoate levels	4	0.501 (0.328, 0.766)	0.0014	0.308 (0.053, 1.773)	0.318	1.748	0.626	0.043	0.630
N-carbamoylalanine levels	7	0.479 (0.298, 0.769)	0.0023	0.999 (0.051, 19.567)	0.999	10.042	0.123	-0.064	0.644
Sphingomyelin (d18:0/20:0, d16:0/22:0) levels	9	0.741 (0.622, 0.884)	0.0008	0.750 (0.531, 1.058)	0.145	5.545	0.698	-0.002	0.944
Glucuronide of piperine metabolite C17H21NO3 levels	4	2.525 (1.664, 3.831)	1.34E-05	1.519 (0.273, 8.459)	0.680	1.698	0.637	0.051	0.611
Hydroxypalmitoyl sphingomyelin (d18:1/16:0(OH)) levels	10	0.503 (0.349, 0.726)	0.0002	0.407 (0.053, 3.100)	0.411	15.051	0.090	0.019	0.840
Mannose levels	7	0.673 (0.523, 0.866)	0.0021	0.488 (0.334, 0.711)	0.014	8.496	0.204	0.053	0.099
X-12306 levels	4	1.912 (1.306, 2.799)	0.0009	2.504 (0.471, 13.320)	0.394	1.650	0.648	-0.029	0.776
X-12822 levels	5	1.562 (1.257, 1.942)	5.89E-05	1.924 (1.248, 2.968)	0.060	2.752	0.600	-0.040	0.355
X-15486 levels	5	1.899 (1.354, 2.663)	0.0002	2.878 (1.350, 6.134)	0.071	5.595	0.231	-0.057	0.320
X-21312 levels	6	1.563 (1.175, 2.080)	0.0021	2.243 (0.838, 6.005)	0.183	6.630	0.250	-0.055	0.493
Phosphate to mannose ratio	4	1.736 (1.344, 2.242)	2.41E-05	2.473 (1.181, 5.181)	0.138	1.805	0.614	-0.064	0.422